Hoffmann-La Roche's German subsidiary reverted to normal expansion in 1994, after a downturn in 1993. Total sales of the unit improved by 11% to 1.2 billion Deutschemarks ($853.2 million), and 1995 sales are projected at over 1.3 billion marks. Drugs accounted for 60% of turnover.
Roche says that while prices remain depressed, the prescribing of innovative drugs by German doctors has recovered, and adds that a series of new launches have contributed to higher volume, especially in the case of the genetically-engineered cystic fibrosis drug Pulmozyme (dornase alfa) and the antibiotic Globocef (cefetamet pivoxil).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze